Glycogen synthase kinase-3 in insulin and Wnt signalling: a double-edged sword?
- PMID: 15494020
- PMCID: PMC4485494
- DOI: 10.1042/BST0320803
Glycogen synthase kinase-3 in insulin and Wnt signalling: a double-edged sword?
Abstract
Glycogen synthase kinase-3 is an unusual protein serine/threonine kinase that, unlike most of its 500-odd relatives in the genome, is active under resting conditions and is inactivated upon cell stimulation. The two mammalian isoforms, GSK-3alpha and beta, play largely overlapping roles and have been implicated in a variety of human pathologies, including Type II diabetes, Alzheimer's disease, bipolar disorder and cancer. Recently, the modes of regulation of this enzyme have been elucidated through a combination of structural and cell biological studies. A series of relatively selective small molecules have facilitated chemical manipulation of the enzyme in intact cells and tissues, and new roles for the protein kinase in embryonic stem cell differentiation and motility have emerged. Despite these advances, the therapeutic value of this enzyme as a drug target remains clouded by uncertainty over the potential of antagonists to promote tumorigenesis. This article describes the state of understanding of this intriguing enzyme, and weighs current evidence regarding whether there is a therapeutic window for amelioration of diseases in which it is implicated, in the absence of inducing new pathologies.
Figures



Similar articles
-
Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis.EMBO J. 2005 Apr 20;24(8):1571-83. doi: 10.1038/sj.emboj.7600633. Epub 2005 Mar 24. EMBO J. 2005. PMID: 15791206 Free PMC article.
-
Glycogen synthase kinase 3: a key regulator of cellular fate.Cell Mol Life Sci. 2007 Aug;64(15):1930-44. doi: 10.1007/s00018-007-7045-7. Cell Mol Life Sci. 2007. PMID: 17530463 Free PMC article. Review.
-
The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.Biomed Pharmacother. 2020 Aug;128:110249. doi: 10.1016/j.biopha.2020.110249. Epub 2020 May 26. Biomed Pharmacother. 2020. PMID: 32470749
-
[A new target for diabetes therapy: advances in the research of glycogen synthase kinase-3 inhibitors].Yao Xue Xue Bao. 2007 Dec;42(12):1227-31. Yao Xue Xue Bao. 2007. PMID: 18338632 Review. Chinese.
-
Inhibition of glycogen synthase kinase-3.Methods Mol Biol. 2008;468:67-75. doi: 10.1007/978-1-59745-249-6_5. Methods Mol Biol. 2008. PMID: 19099246
Cited by
-
Potential synaptic plasticity-based Shenzhiling oral liquid for a SAD Mouse Model.Brain Behav. 2019 Sep;9(9):e01385. doi: 10.1002/brb3.1385. Epub 2019 Aug 20. Brain Behav. 2019. PMID: 31429527 Free PMC article.
-
Casein Kinase II (CK2), Glycogen Synthase Kinase-3 (GSK-3) and Ikaros mediated regulation of leukemia.Adv Biol Regul. 2017 Aug;65:16-25. doi: 10.1016/j.jbior.2017.06.001. Epub 2017 Jun 13. Adv Biol Regul. 2017. PMID: 28623166 Free PMC article. Review.
-
Bone Cell Bioenergetics and Skeletal Energy Homeostasis.Physiol Rev. 2017 Apr;97(2):667-698. doi: 10.1152/physrev.00022.2016. Physiol Rev. 2017. PMID: 28202599 Free PMC article. Review.
-
Phosphorylation of GSK-3beta by cGMP-dependent protein kinase II promotes hypertrophic differentiation of murine chondrocytes.J Clin Invest. 2008 Jul;118(7):2506-15. doi: 10.1172/JCI35243. J Clin Invest. 2008. PMID: 18551195 Free PMC article.
-
Neurological characterization of mice deficient in GSK3α highlight pleiotropic physiological functions in cognition and pathological activity as Tau kinase.Mol Brain. 2013 May 25;6:27. doi: 10.1186/1756-6606-6-27. Mol Brain. 2013. PMID: 23705847 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical